10.28.25 -- Driving Prostate Cancer Innovation Through Immunotherapy

AI is transforming cell therapy manufacturing and enabling more personalized treatments. Explore how to navigate innovation in a fast-moving therapeutic landscape with actionable insights.

Discover the potential of T1 cell-derived nanoparticles (CDNPs) to accelerate T-cell activation. See how CDNPs’ unique mechanism of mimicking physiological immune stimulation positions them for broad use.

Next-generation mRNA platforms transform vaccine manufacturing, improving sustainability, accessibility, production efficiency, and adaption to health threats. thereby advancing public health outcomes.

Cleanroom systems are purposely designed to simplify the implementation of the aseptic manufacturing space that the industry needs to meet future sterile injectable capacity demand.

A feeder-free medium and closed processing system can expand and process primary human NK cells for clinical use, helping researchers overcome a key bottleneck in cell therapy manufacturing.

When it comes to process development, timing, technology, partners, and strategic planning all merit careful and deliberate consideration. See expert insights into these three crucial factors.

Harnessing the body’s own immune system, researchers are developing personalized cell therapies to target solid tumors, using a patient’s unique mutations to create powerful, individualized treatments.

Despite advancements in AAV-based gene therapy, key aspects of AAV biology and production remain unclear. Find out how researchers are exploring HEK293 subclones to identify traits that enhance viral vector yields.

In the evolving world of biopharmaceutical manufacturing, understand how single-use filtration remains a vital yet overlooked process essential to ensuring product purity and patient safety.

Endonucleases are essential for clearing DNA impurities in viral vector manufacturing. Grasp how a new enzyme compares to other commercially available options in AAV and LVV production.

Utilize a system that automates CAR-T cell production using flow cytometry and analyzers for precise monitoring as well as learn about the sample preparation, instrument setup, and data analysis.

Access a flexible aseptic processing system that provides modular, semi-automated, and fully automated solutions to meet demands at all stages of development.

Gain insight into how a novel approach to VLP manufacturing can overcome common scalability and consistency issues, enabling high yields and potent gene editing in a single day.